Free Trial

N4 Pharma (N4P) Competitors

N4 Pharma logo
GBX 0.55 +0.03 (+4.76%)
(As of 12/20/2024 09:50 AM ET)

N4P vs. RGT, HELD, HLN, HIK, HCM, INDV, AMYT, AGY, APH, and BXP

Should you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Argent BioPharma (RGT), Hellenic Dynamics (HELD), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), and Beximco Pharmaceuticals (BXP). These companies are all part of the "drug manufacturers - specialty & generic" industry.

N4 Pharma vs.

N4 Pharma (LON:N4P) and Argent BioPharma (LON:RGT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.

N4 Pharma received 103 more outperform votes than Argent BioPharma when rated by MarketBeat users.

CompanyUnderperformOutperform
N4 PharmaOutperform Votes
103
65.61%
Underperform Votes
54
34.39%
Argent BioPharmaN/AN/A

In the previous week, N4 Pharma's average media sentiment score of 0.00 equaled Argent BioPharma'saverage media sentiment score.

Company Overall Sentiment
N4 Pharma Neutral
Argent BioPharma Neutral

N4 Pharma has a beta of -0.37, indicating that its stock price is 137% less volatile than the S&P 500. Comparatively, Argent BioPharma has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.

1.1% of Argent BioPharma shares are owned by institutional investors. 18.0% of N4 Pharma shares are owned by company insiders. Comparatively, 17.8% of Argent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Argent BioPharma's return on equity of 0.00% beat N4 Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
N4 PharmaN/A -82.39% -56.00%
Argent BioPharma N/A N/A -108.57%

N4 Pharma has higher revenue and earnings than Argent BioPharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
N4 Pharma£23.52K92.30-£1.08MN/AN/A
Argent BioPharmaN/AN/A-£17.53M-£0.24-23.67

Summary

N4 Pharma beats Argent BioPharma on 5 of the 9 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

N4P vs. The Competition

MetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£2.17M£1.17B£5.14B£1.91B
Dividend Yield3.12%3.04%5.09%5.45%
P/E Ratio-55.00131.2390.051,867.09
Price / Sales92.301,981.001,116.25393,302.55
Price / Cash2.2510.2543.1028.64
Price / BookN/A3.084.782.81
Net Income-£1.08M£152.21M£120.31M£155.77M
7 Day Performance-8.33%-0.48%-1.92%-2.02%
1 Month Performance-21.43%-1.88%13.65%21.67%
1 Year Performance-40.48%98.32%28.34%29.76%

N4 Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
N4P
N4 Pharma
N/AGBX 0.55
+4.8%
N/A-38.9%£2.17M£23,524.00-55.005Gap Up
RGT
Argent BioPharma
N/AGBX 6.50
-7.1%
N/AN/A£3.49MN/A-27.08N/AGap Down
High Trading Volume
HELD
Hellenic Dynamics
N/AGBX 0.95
flat
N/AN/A£1.40MN/A0.00N/A
HLN
Haleon
0.6406 of 5 stars
N/AGBX 415
+∞
+18.8%£34.43B£11.26B3,165.0025,408
HIK
Hikma Pharmaceuticals
1.5471 of 5 stars
GBX 1,938
+0.2%
GBX 2,383.33
+23.0%
+9.2%£4.30B£3.02B2,981.549,100News Coverage
HCM
HUTCHMED
N/AGBX 239
-3.2%
N/A-11.7%£2.04B£610.81M-5,975.001,760
INDV
Indivior
2.4989 of 5 stars
GBX 950
+4.6%
GBX 1,500
+57.9%
-21.9%£1.22B£1.15B-1,187.501,000Analyst Forecast
AMYT
Amryt Pharma
N/AGBX 143
-11.7%
N/AN/A£457.11M£210.24M-4.33290Gap Down
AGY
Allergy Therapeutics
N/AGBX 6.40
+3.2%
N/A+220.0%£305.28M£53.26M-106.67612
APH
Alliance Pharma
3.3054 of 5 stars
GBX 48.40
+0.4%
GBX 60
+24.0%
+17.3%£261.64M£183.15M-806.6791,000News Coverage
Positive News
BXP
Beximco Pharmaceuticals
N/AGBX 36.50
flat
N/A-14.6%£162.83M£43.08B456.255,500News Coverage

Related Companies and Tools


This page (LON:N4P) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners